津力达颗粒联合通心络胶囊治疗糖尿病视网膜病变的临床观察

目的:观察津力达颗粒联合通心络胶囊对2型糖尿病非增殖期视网膜病变患者临床疗效、中医证候、糖脂代谢、胰岛素抵抗指数及血清白细胞介素-6(IL-6)的影响。方法:将62例2型糖尿病非增殖期视网膜病变患者随机分为两组,均给予基础治疗。对照组32例给予羟苯磺酸钙胶囊治疗,治疗组30例在对照组的基础上加用津力达颗粒联合通心络胶囊治疗。两组患者连续用药12周后统计临床疗效及中医证候改善情况,并观察空腹血糖(FPG),餐后2 h血糖(2 h PG),糖化血红蛋白(Hb A1c),三酰甘油(TG),总胆固醇(TC),高密度脂蛋白(HDL-C),低密度脂蛋白(LDL-C),胰岛素抵抗指数,IL-6的变化情况。结果:治疗组临床疗效及中医证候改善情况明显高于对照组(P0.05);两组患者治疗后FPG,2 h PG,Hb A1c,TG,TC,LDL-C水平,胰岛素抵抗指数,IL-6水平均较本组治疗前明显降低,HDL-C水平较本组治疗前明显升高,且治疗组优于对照组(P0.05)。结论:津力达颗粒联合通心络胶囊治疗2型糖尿病非增殖期视网膜病变疗效明显,其作用可能与调节糖脂代谢、改善胰岛素抵抗和降低血清炎症因子有关。

Clinical Observation of Jinlida Granule Combined with Tongxinluo Capsule on Diabetic Retinopathy

Objective: To observe the clinical efficacy and effect of Jinlida granule combined with Tongxinluo capsule on traditional Chinese medicine (TCM) syndromes, glucose metabolism, lipid metabolism and levels of interleukin-6(IL-6) in serum of patients with non-proliferative retinopathy of type 2 diabetes. Method: The 62 patients with non-proliferative retinopathy of type 2 diabetes were randomly divided into two groups, and all of them were given with basic treatment. The control group (32 patients) were treated with calcium hydroxybenzene sulfonate capsule, and the treatment group (30 patients) were treated with Jinlida granule combined with Tongxinluo capsule on the basis of control group. After 12 weeks, clinical efficacy, TCM syndromes improvement, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbA1c), triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein-C (HDL-C), low-density lipoprotein-C (LDL-C), insulin resistance index (HOMA-IR) and IL-6 in two groups were observed and compared. Result: The clinical efficacy and the improvement of TCM syndromes in treatment group were significantly better than those in control group (P<0.05). The FPG, 2 hPG, HbA1c, TG, TC, HDL-C, insulin resistance index and IL-6 were significantly decreased, and the HDL-C was significantly increased in both groups after treatment, and the treatment group were better than control group (P<0.05). Conclusion: Jinlida granule combined with Tongxinluo capsule has a significant therapeutic effect on non-proliferative retinopathy of type 2 diabetes, and the mechanism may be related to regulating glucose and lipid metabolism, improving insulin resistance and reducing serum inflammatory factors.